Investigation of the Impact of Medications Used in COVID-19 Treatment and COVID-19 Vaccine on Hearing

November 19, 2025 updated by: Azize Arzu KÖROĞLU KOÇYİĞİT, Zonguldak Bulent Ecevit University
Investigation of the Impact of Medications Used in COVID-19 Treatment and COVID-19 Vaccine on Hearing

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This study aims to investigate the impact of medications containing the active ingredients hydroxychloroquine and favipiravir on the auditory system, as well as to examine the effect of COVID-19 on hearing and its potential relationship with medication use and COVID-19 vaccine dose.

Study Type

Observational

Enrollment (Actual)

90

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

  1. Those who have had COVID-19 and are taking medication
  2. Those who have had COVID-19 and are not taking medication
  3. Healthy individuals who have not had COVID-19

Description

Inclusion Criteria:

Age between 18 and 35 For the Medication group: Having had COVID-19 and using COVID-19 medications For the Non-Medication group: Having had COVID-19 and not using COVID-19 medications For the Control group: Having never had COVID-19

Exclusion Criteria:

Previously diagnosed with hearing loss Use of ototoxic medications other than those specified Pathology detected during tympanometric evaluation or otoscopic examination Chronic disease Family history of hearing loss History of meningitis Neurological disorders Acute or chronic ear infection Admission to intensive care

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Control group
Group that has not had Covid-19
Diagnostic test: Hearing tests
Participants' pure tone thresholds, high frequency thresholds, and otoacoustic emissions measurements were evaluated.
Medication Group
The group that had Covid-19 and used medication
Diagnostic test: Hearing tests
Participants' pure tone thresholds, high frequency thresholds, and otoacoustic emissions measurements were evaluated.
Non-medication group
The group that had Covid-19 and did not use medication
Diagnostic test: Hearing tests
Participants' pure tone thresholds, high frequency thresholds, and otoacoustic emissions measurements were evaluated.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Pure tone and high frequency hearing thresholds
Time Frame: December, 2021-February 2022
December, 2021-February 2022
Transient evoked otoacoustic emissions - Signal/noise ratio
Time Frame: December, 2021-February 2022
December, 2021-February 2022
Distortion product otoacoustic emissions- signal/noise ratio
Time Frame: December, 2021-February 2022
December, 2021-February 2022

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Zonguldak Bulent Ecevit University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2021

Primary Completion (Actual)

February 1, 2022

Study Completion (Actual)

March 1, 2022

Study Registration Dates

First Submitted

September 26, 2025

First Submitted That Met QC Criteria

November 19, 2025

First Posted (Actual)

November 28, 2025

Study Record Updates

Last Update Posted (Actual)

November 28, 2025

Last Update Submitted That Met QC Criteria

November 19, 2025

Last Verified

November 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2021/61-18
  • 1919B012102481 (Other Grant/Funding Number: TUBİTAK)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Ototoxicity

Clinical Trials on Hearing tests

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovakia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe